Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tegoprazan - HK inno.N/RaQualia Pharma

Drug Profile

Tegoprazan - HK inno.N/RaQualia Pharma

Alternative Names: CJ-12420; IN-A001; K-CAB; LXI-15028; RQ-00000004; RQ-4

Latest Information Update: 02 Aug 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer CJ Cheiljedang Corp.; HK inno.N; RaQualia Pharma; Shandong Luoxin Pharmaceutical
  • Class Amides; Anti-inflammatories; Antibacterials; Antiulcers; Benzimidazoles; Benzopyrans; Fluorobenzenes; Small molecules
  • Mechanism of Action H(+) K(+)-exchanging ATPase inhibitors; Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erosive oesophagitis; Gastro-oesophageal reflux
  • Phase III Gastric ulcer; Helicobacter infections

Most Recent Events

  • 05 Aug 2020 HK inno.N Corporation plans a phase I trial in September 2020 (PO) (NCT04494269)
  • 29 Jun 2020 Tegoprazan licensed to HK inno.N worldwide
  • 18 Jun 2020 CJ HealthCare is now called HK inno.N
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top